Panel of Independent Experts to Evaluate Eli Lilly's Donanemab for Alzheimer's Treatment
Friday, 8 March 2024, 11:45
FDA Postpones Decision
The Food and Drug Administration (F.D.A.) has postponed the approval decision for Eli Lilly’s donanemab, a promising Alzheimer's drug.
Panel of Independent Experts
The agency has decided to convene a panel of independent experts to evaluate the safety and efficacy of the drug.
Anxiety Among Stakeholders
The postponement has left stakeholders anxious about the outcome of the evaluation, raising concerns in the medical and financial communities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.